

Product Name: Daclatasvir (BMS-790052) Revision Date: 01/10/2021



Daclatasvir (BMS-790052)

20

Cat. No.:	A5618
CAS No.:	1009119-64-5; 1214735-16-6
Formula:	C40H50N8O6
M.Wt:	738.88
Synonyms:	
Target:	Proteases
Pathway:	HCV Protease
Storage:	Store at -20°C

Solvent & Solubility

	≥36.6 mg/mL in DM	\geq 36.6 mg/mL in DMSO; insoluble in H2O; \geq 23.33 mg/mL in EtOH with ultrasonic			
	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg
	Slock Solutions	1 mM	1.3534 mL	6.7670 mL	13.5340 mL
	a19	5 mM	0.2707 mL	1.3534 mL	2.7068 mL
	PELE	10 mM	0.1353 mL	0.6767 mL	1.3534 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	HCV NS5A inhibitor		
IC ₅₀ & Target	9 pM-50 pM(EC50) (HCV NS5A)		
	Cell Viability Assay		
	Cell Line:	HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture	
	Preparation method:	The solubility of this compound in DMSO is > 36.6 mg/mL. General tips for	
In Vitro		obtaining a higher concentration: Please warm the tube at 37 $^\circ\mathrm{C}$ for 10 minutes	
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored	
		below -20°C for several months.	
	Reacting conditions:	EC50: 9 to 146 pM	
		1 www.apexbt.com	

1 | www.apexpt.com

	Applications:	BMS-790052 exhibited picomolar half-maximum effective concentrations towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture, with EC50 values ranging from 9 to 146 pM. BMS-790052 displayed similar potency in Huh-7, HeLa and HEK293T		
	Animal experiment	cells.		
In Vivo	Animal models:	patients chronically infected with HCV		
	Dosage form:	Oral administration, 10-100 mg		
	Applications:	BMS-790052 was safe and well tolerated in HCV-infected subjects after single oral doses up to 100 mg. In HCV-infected subjects, BMS-790052 had a mean plasma elimination half-life ranging from 10 to 14 h. Administration of a single 100-mg dose of BMS-790052 was associated with a 3.3log 10 reduction in mean viral load measured 24h post-dose that was sustained for an additional 120h in two patients infected with genotype 1b virus.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility slightly differ with the theoretical value. This is caused by an experime system error and it is normal.		

Product Citations

See more customer validations on www.apexbt.com.



PEBIC

References

[1]. Gao M, Nettles R E, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect[J]. Nature, 2010, 465(7294): 96.

Caution

FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.













